Axovant Appoints David Nassif as Chief Financial Officer and Expands Board of Directors
July 01 2019 - 7:00AM
Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage
company developing innovative gene therapies, today announced the
appointment of David Nassif as Chief Financial Officer, effective
July 1, 2019. In addition, Axovant announced the expansion of its
Board of Directors with the addition of Mr. Senthil Sundaram.
“Since the inception of Axovant Gene Therapies,
we have been focused on building an industry leading team to
develop and commercialize gene therapies,” said Dr. Pavan Cheruvu,
Chief Executive Officer of Axovant. “We are thrilled to welcome
David as CFO and believe his diverse experience in the
biopharmaceutical sector across both development and commercial
stage companies ideally complements and strengthens our management
team. We are also pleased to have Senthil join our board, as he
brings important industry perspectives with an impressive career in
corporate finance and strategy, most recently in his role at
Nightstar through its acquisition by Biogen. Together, these
additions support the rapid development of our clinical gene
therapies to transform the lives of patients and their
families.”
Mr. Nassif has more than 25 years of life
sciences industry experience in executive financial management
roles in development-stage, commercial-stage, public and private
companies. Prior to joining Axovant, Mr. Nassif was Executive Vice
President and Chief Financial Officer of SteadyMed Therapeutics,
where he was instrumental in its acquisition by United Therapeutics
in August 2018. From 2011 to 2014, Mr. Nassif served as the
President and Chief Financial Officer of Histogen. Previously, he
was Executive Vice President and Chief Financial Officer of Zogenix
and held several key roles at Amphastar Pharmaceuticals and RealAge
Inc. Earlier in his career, Mr. Nassif held various positions with
Cypros Pharmaceuticals, where he was instrumental in leading its
merger with Ribogene, Inc. to form Questcor Pharmaceuticals, Inc.
He holds a B.S. in Finance and Management Information Systems with
honors from the University of Virginia and a J.D. from the
University of Virginia School of Law.
Mr. Sundaram was most recently the Chief
Financial Officer at Nightstar Therapeutics, until its acquisition
by Biogen in June 2019. While at Nightstar, he was responsible for
corporate finance and operations, business development, and
strategy. He helped lead the execution of multiple equity
offerings, as well as licensing and M&A transactions. Prior to
joining Nightstar, Mr. Sundaram was the Vice President and Head of
Business and Corporate Development at Intercept Pharmaceuticals,
Inc. Previously, Mr. Sundaram spent 13 years in the healthcare
investment banking groups at Lehman Brothers/Barclays, Citigroup
and Lazard. Mr. Sundaram holds a B.S. in Computer Engineering and a
B.A. in Economics from Brown University.
About Axovant Gene
Therapies
Axovant, part of the Roivant family of
companies, is a clinical-stage gene therapy company focused on
developing a pipeline of innovative product candidates for
debilitating neurological diseases. Our current pipeline of gene
therapy candidates targets Parkinson’s disease, GM1 gangliosidosis
and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff
disease). Axovant is focused on accelerating product candidates
into and through clinical trials with a team of experts in gene
therapy development and through external partnerships with leading
gene therapy organizations. For more information, visit
www.axovant.com.
About Roivant
Roivant Sciences aims to improve health by
rapidly delivering innovative medicines and technologies to
patients. It does this by building Vants – nimble, entrepreneurial
biotech and healthcare technology companies with a unique approach
to sourcing talent, aligning incentives, and deploying technology
to drive greater efficiency in R&D and commercialization. For
more information, please visit www.roivant.com.
Contacts:
Media and InvestorsTricia
TruehartAxovant(631) 892-7014investors@axovant.com
media@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Jul 2023 to Jul 2024